logo-loader
viewANGLE PLC

ANGLE inks agreement with world-leading molecular testing provider

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), discusses with Proactive their co-marketing agreement with QIAGEN NV, a world-leading provider of molecular testing solutions.

The initial focus will be on prostate and breast cancer research applications.

The agreement will see both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.

Quick facts: ANGLE PLC

Price: 61.45 GBX

AIM:AGL
Market: AIM
Market Cap: £106.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read